

1493 Rec'd PGT/PTO 07 DEC 2005

96

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: December 2, 2005

Signature:

(Michael H. Teschner)

Docket No.: SEDERM 3.3-010  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Karl Lintner

Application No.: 10/523,333

Group Art Unit: N/A

Filing Date: January 28, 2005

Examiner: Not Yet  
Assigned

For: COSMETIC OR DERMOPHARMACEUTICAL  
COMPOSITIONS CONTAINING KOMBUCHA

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

It is respectfully requested that the references listed on the enclosed Form PTO-1449 be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each non-US reference is enclosed. These references were cited in the background section of the present specification and/or a corresponding International Search Report, a copy of which is enclosed. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account No. 12-1095.

Dated: December 2, 2005

Respectfully submitted,

By

Michael H. Teschner

Registration No.: 32,862

LERNER, DAVID, LITTENBERG,


KRUMHOLZ & MENTLIK, LLP

600 South Avenue West

Westfield, New Jersey 07090

(908) 654-5000

Attorney for Applicant



PTO/SB/08a/b (07-05)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2	Attorney Docket Number	SEDERM 3.3-010
-------	---	----	---	------------------------	----------------

### Complete if Known

Application Number	10/523,333
Filing Date	January 28, 2005
First Named Inventor	Karl Lintner
Art Unit	N/A
Examiner Name	Not Yet Assigned
Attorney Docket Number	SEDERM 3.3-010

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA*	US-5,607,980-A1	04-04-1997	McAtee et al.	
	AB*	US-3,821,372-A	06-28-1974	Vanlerberghe et al.	

### FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO-99/62478-A1	12-09-1999	Beiersdorf AG		
	BB	WO-00/62743-A2	10-26-2000	The Proctor & Gamble Company		√
	BC	FR-2 315 991-A	01-28-1977	L'Oreal		**
	BD	FR-1.477.048-A	04-14-1967	L'Oreal		
	BE	FR-2.091.516-A	01-14-1972	L'Oreal		1A
	BF	WO-83/01571-A1	05-11-1983	The Regents Of The University Of California		√
	BG	WO-92/08685-A1	05-29-1992	L'Oreal		**
	BH	FR-2 465 780-A	03-27-1981	L'Oreal		**
	BI	FR-2,482,128-A1	01-13-1981	L'Oreal		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	DUFRESNE et al., "Tea, Kombucha, and health: a review.", Food Research International, Vol. 33, No. 6, pgs. 409-421, 2000	
	CB	FONTANA et al., "Acetobacter Cellulose Pellicle as a Temporary Skin Substitute", Applied biochemistry and Biotechnology, Vol. 25-25, pgs. 253-64, 1990	
	CC	SADJADI, J., "Cutaneous Anthrax Associated With the Kombucha "Mushroom" in Iran:", Journal of the American Medical Association, Vol. 280, No. 18, pgs. 1567-1568, 11 November 1998	
	CD	STEINKRAUSE et al., "Investigations into the Antibiotic Activity of Tea Fungus/Kombucha Beverage", Acta Biotechnol, Vol. 16, No. 2-3, pgs. 199-205, 1996	
	CE	THORPE et al., "Role of the Maillard reaction in diabetes mellitus and diseases of aging", Drugs Aging, Vol. 9, No. 2, , pgs. 67-77, August 1996	
	CF	NAGATAJ et al., "Protein Cross-linking by the Maillard Reaction", The journal of Biological Chemistry, Vol. 371, No. 32, pgs. 19338-19345, 1996	
	CG	FRANK, "instructions pratiques de preparation et d'utilisation"	
	CH	HAGER et al., "Hagers Handbunch der Pharmazeutischen Praxis fur Apotheker", 1973	
	CI	BROWNLEE et al., "Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking, Vol. 232 (4758), pgs. 1269-1632, June 27, 1986	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	10/523,333
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	January 28, 2005
				First Named Inventor	Karl Lintner
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	SEDERM 3.3-010

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

\*With English Abstract Only

1A US 3,821,372 is an English Counterpart

613469.1

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--